EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation, wild-type sparing, irreversible EGFR tyrosine kinase inhibitor (TKI), has been shown to improve outcomes after 1st or 2nd EGFR-TKI of metastatic NSCLC with T790M mutation as an ARM in first line setting of metastatic NSCLC with common and uncommon EGFR mutation, as well as in adjuvant setting in Resected EGFR-Mutated NSCLC 8.